Evidence map›Paper›PMID 26376131›Full record

ReviewKidney international2015

Probiotics and chronic kidney disease.

Laetitia Koppe, Denise Mafra, Denis Fouque

4 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 135 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 6 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02929225 early_phase1completednot on this mapstarted 2016, after this paper: background citation

Effect of Probiotics on Modulating the Bacterial Translocation and Improving Micro-inflammation in Hemodialysis Patients

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2016 to 2018Enrolled50ConditionsKidney Failure, ChronicArmsBifid Triple Viable Capsules, placebo
NCT03010696 completednot on this map

The Correlation Between Gut Microbiome/Metabolite and End Stage Renal Disease (ESRD)

TypeobservationalSponsorChina Agricultural UniversityRan2015 to 2017Enrolled293ConditionsKidney Failure, ChronicArmsNo interventions, questionnaire, collect specimen
NCT03010735 phase2 / phase3completednot on this map

Effects of Probiotics on Metabolism of Uremic Toxin in Patients With End Stage Renal Disease (ESRD)

TypeinterventionalSponsorChina Agricultural UniversityRan2015 to 2017Enrolled150ConditionsKidney Failure, ChronicArmsprobiotics, Placebo
NCT03877081 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Effect of Probiotics and Prebiotics in Renal Function in Septic Acute Kidney Injury Patients, Randomized Control Trial

TypeinterventionalSponsorHospital Civil de GuadalajaraRan2019 to 2023Enrolled90ConditionsAcute Kidney Injury, Probiotics, SepsisArmsProbiotics, Placebo
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 6 syntheses or guidelines pooled it, 257 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Gut microbes · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Supplementation withThe veterinary quarterly · 2026
    Article
  18. Review
  19. Article
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Laetitia KoppeDepartment of Nephrology and Nutrition, Centre Hospitalier Lyon SUD, Carmen, CENS, Univ Lyon, UCBL, Pierre Bénite, France.
Denise MafraMedical Sciences and Cardiovascular Sciences Graduate Programs, Federal University Fluminense (UFF), Niterói-RJ, Brazil.
Denis FouqueDepartment of Nephrology and Nutrition, Centre Hospitalier Lyon SUD, Carmen, CENS, Univ Lyon, UCBL, Pierre Bénite, France.
Université Claude Bernard Lyon 1 · FRUniversidade Federal Fluminense · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probiotics are the focus of a thorough investigation as a natural biotreatment due to their various health-promoting effects and inherent ability to fight specific diseases including chronic kidney disease (CKD). Indeed, intestinal microbiota has recently emerged as an important player in the progression and complications of CKD. Because many of the multifactorial physiological functions of probiotics are highly strain specific, preselection of appropriate probiotic strains based on their expression of functional biomarkers is critical. The interest in developing new research initiatives on probiotics in CKD have increased over the last decade with the goal of fully exploring their therapeutic potentials. The efficacy of probiotics to decrease uremic toxin production and to improve renal function has been investigated in in vitro models and in various animal and human CKD studies. However to date, the quality of intervention trials investigating this novel CKD therapy is still lacking. This review outlines potential mechanisms of action and efficacy of probiotics as a new CKD management tool, with a particular emphasis on uremic toxin production and inflammation.

Indexed as

DysbiosisGastrointestinal TractHumansIndolesInflammationMicrobiotaPhenolsProbioticsRenal Insufficiency, ChronicToxins, BiologicalUremiaIndolesPhenolsToxins, Biological

Identifiers

PMID26376131
OpenAlexW1763735003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.